Inflammatory bowel disease in the elderly

Aging Health

Volumn 3, Issue 1, 2007, Pages 77-84

  Evans, Paul E ^a   Pardi, Darrell S ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

6 mercaptopurine; Azathioprine; Budesonide; Corticosteroid; Crohn's disease; Cyclosporine; Diagnosis; Elderly; Epidemiology; Inflammatory bowel disease; Infliximab; Mesalamine; Methotrexate; Sulfasalazine; Treatment; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; DIGITALIS; DIGOXIN; ENEMA; ESTROGEN; GOLD; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; NICOTINE PATCH; NONSTEROID ANTIINFLAMMATORY AGENT; OLSALAZINE; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE; SODIUM DIHYDROGEN PHOSPHATE; STEROID; TACROLIMUS; UNINDEXED DRUG;

ABDOMINAL PAIN; ANEMIA; BLOOD TRANSFUSION; BLOODY DIARRHEA; BONE DENSITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLITIS; COLON RESECTION; COLONOSCOPY; COMORBIDITY; CROHN DISEASE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; DIVERTICULOSIS; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; ELDERLY CARE; ENTERITIS; FEVER; FLUID RESUSCITATION; HEART FAILURE; HEPATITIS; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; INTERSTITIAL NEPHRITIS; ISCHEMIC COLITIS; LIFESTYLE MODIFICATION; META ANALYSIS; MICROSCOPIC COLITIS; MONOTHERAPY; MORTALITY; NEPHROLITHIASIS; NEPHROTOXICITY; NUTRITIONAL SUPPORT; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PANCREATITIS; PROGNOSIS; RECTUM HEMORRHAGE; REMISSION; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TENESMUS; TOXIC MEGACOLON; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION;

EID: 33847267666     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/1745509X.3.1.77     Document Type: Review

References (60)

1. Russel M, Stockbrugger R: Epidemiology of inflammatory bowel disease: an update. Scand. J. Gastroentol 31, 417-427 (1996).
2. Loftus EV, Silverstein M, Sandborn W, Tremaine W, Harmsen W. Zinsmeister A: Crohn's disease in Olmsted County, Minnesota. 1940-1993: Incidence, prevalence. and survival. Gastroenterology 114, 1161-1168 (1998).
3. Loftus EV, Silverstein M, Sandborn W, Tremaine W, Harmsen W, Zinsmeister A: Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut 46, 336-343 (2000).
4. Piront P, Louis E, Latour P, Plomteux O, Belaiche J: Epidemiology of inflammatory bowel diseases in the elderly in the province of Liege: a three-year prospective study. Gastroenterol. Clin. Biol, 25, 157-161 (2001).
5. Softley A, Myren J, Clamp S, Boucher I, Watkinson G, Dombal F: Inflammatory bowel disease in the elderly patient. Scand. J Gastroenterol. 23(Suppl. 144), 27-30 (1988).
6. Gupta S, Saverymuttu S, Keshavarzian A, Hodgson H: Is the pattern of inflammatory bowel disease different in the elderly? Age Ageing 14, 366-370 (1985).
7. Loftus E, Sandborn W. Epidemiology of inflammatory bowel disease. Gastroenterol. Clin. North Am. 31, 1-20 (2002).
8. Pardi D: Microscopic colitis an update. Inflamm. Bowel Dis. 10, 860-870 (2004).
9. Wagtmans MJ, Verspaget H, Lamers C, van Hogezand R: Crohn's disease in the elderly: a comparison with young adults. J. Clin. Gastroenterol. 27, 129-133 (1998).
10. Harper PC, McAuliffe T, Beeken W: Crohn's disease in the elderly: a statistical comparison with younger patients matched for sex and duration of disease. Arch. Intern. Med. 146, 753-755 (1986).
11. Tedesco FJ, Hardin RD, Harper RN, Edwards BH: Infectious colitis endoscopically simulating inflammatory bowel disease: a prospective evaluation. Gastrointest. Endo. 29, 195-197 (1983).
12. Schumacher G, Sandstedt B, Kollberg B: A prospective study of first attacks of inflammatory bowel disease and infectious colitis: clinical findings and early diagnosis. Scand. J. Gastroenterol. 29, 265-274 (1994).
13. Manousos ON, Truelove S, Lumsden K: Prevalence of colonic diverticulosis in the general population of the Oxford area. BMJ 3, 762-763 (1967).
14. Heresbach D, Alexandre J, Bretagne J et al.: Crohn's disease in the over-60 age group: a population based study. Eur J. Gastroenterol. Hepatol. 16, 657-664 (2004).
15. Koutroubakis IE, Antoniou P, Tzardi M, Kouroumalis E: The spectrum of segmental colitis associated with diverticulosis. Int. J. Colorectal. Dis. 20, 28-32 (2005).
16. Sultan K, Fields S, Panagopoulos G, Korelitz B: The nature of inflammatory bowel disease in patients with coexistent colonic diverticulosis. J. Clin. Gastroenterol. 40, 317-321 (2006).
17. Pardi DS, Loftus E, Camilleri M: Treatment of inflammatory bowel disease in the elderly. An update. Drugs Aging 19, 355-363 (2002).
18. Greth J, Torok H, Koenig A, Folwaczny C: Comparison of inflammatory bowel disease at younger and older age. Eur. J. Med. Res. 9, 552-554 (2004).
19. Polito JM, Childs B, Mellits E, Tokayer A, Harris M, Bayless T: Crohn's disease: influence of age at diagnosis an site and clinical type of disease. Gastroenterology 111 580-586 (1996).
20. Triantafillidis J, Emmanouilidis A, Nicolakis D. Ifantis T, Cheracakis P, Merikas E: Crohn's disease in the elderly: clinical features and long-term outcome of 19 Greek patients. Digest Liver Dis. 32, 498-503 (2000).
21. Triantaffillidis J, Emmenouilidis A, Pomonis E et al: Ulcerative colitis in the elderly: clinical patterns and outcome in 51 Greek patients. J Gastroenterol. 36. 312-316 (2001).
22. Wolters FL, Russel M, Sijbrandij J et al.: Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut 55, 510-518 (2006).
23. Kornbluth A, Sachar D: Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters.Committee. Am. J Gastroenterol. 99(7), 1371-1385 (2004).
24. Sutherland LR, MacDonald J: Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis (Cochrane Review). In: The Cochrane Library (Issue 3). Update Software, Oxford, UK (2006).
25. Cohen RD, Woseth D, Thisted R, Hanauer S: A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am. J. Gastroenterol. 95, 1263-1276 (2000).
26. Safdi M. DeMicco M, Sninsky C et al.: A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am. J. Gastroenterol. 92, 1867-1871 (1997).
27. Lindgren S, Lofberg R, Bergholm L et al.: Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctits. Scand. J. Gastroenterol. 37, 705-710 (2002).
28. Hawthorne AB, Logan R, Hawkey C et al.: Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 305(6844), 20-22 (1992).
29. George J, Present D, Riccardo P, Bodlan C, Rubin P: The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am. J. Gastroenterol. 91(9), 1711-1714 (1996).
30. Gearry B, Barclay M: Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J. Gastroenterol. Hepatol. 20(8), 1149-1157 (2005).
31. Sandborn WJ: Nicotine therapy for ulcerative colitis: a review of rationale.mechanisms, pharmacology, and clinical results. Am. J. Gastroenterol. 94, 1161-1171 (1999).
32. Cohen RD, Stein R, Hanauer S: Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am. J. Gastroenterol. 94, 1587-1592 (1999).
33. Jarnerot G, Hertervig E, Ingalili F et al.: Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128, 1805-1811 (2005).
34. Loftus C. Loftus E, Sandborn W: Cyclosporin for refractory ulcerative colitis. Gut 52, 172-173 (2003).
35. Rutgeerts P, Sandhom W, Feagan B et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353, 2462-2476 (2005).
36. Greenberg GR, Feagan B, Martin F et al.: Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N. Engl. J. Med. 331, 836-841 (1994).
37. Otley A, Steinhart A: Budesonide for induction of remission in Crohn's disease. In: The Cocchrane Library (Issue 4). Wiley, Chichester, UK (2005).
38. Thomsen OO, Cortot A, Jewell D: A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N. Engl. J Med. 339, 370-374 (1998).
39. Hanauer SB, Stromberg U: Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, place-controlled trials. Clin. Gastroenteral. Hepatol. 2, 379-388 (2004).
40. Pearson DC, May G, Fick G, Sutherland L: Azathioprine for maintaining remission of Crohn's disease. In: The Cochrane Library (Issue 2). Update Software, Oxford, UK (2000).
41. Fraser AG: Methotrexate: first or secondline immunomodulator? Eur. J. Gastroenterol. Hepatol. 15, 225-231 (2003)
42. Hanauer SB, Feagan B, Lichtenstein G et al.: Maintenance infliximab for Crohn's diease: the ACCENT randomized trial. Lancet 359, 1541-1549 (2002).
43. Malchow H, Ewe K, Brandes JW et al.: European Co-operative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 86, 249-266 (1984).
44. Sandborn WJ, Feagan B: Review article: mild to moderate Crohn's disease - defining the basis for a new treatment algorithm. Altiment. Pharmacol. Ther 18, 263-277 (2000).
45. Sandborn WJ, Fazio V, Feagan B, Hanauer S: AGA technical review on perianal crohn's disease. Gastroenterology 125, 1508-1530 (2003).
46. Pearson DC, May G, Fick G, Sutherland L: Azathioprine 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann. Intern. Med. 123, 132-142 (1995).
47. Present DH, Rutgeerts P, Targan S et al.: Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340(18), 1398-1405 (1999).
48. Thomas TPL: The complications of systemic corticosteroid therapy in the elderly. Gerontology 30, 60-65 (1984).
49. Muller A, Stevens P, Mcintyre A, Ellison H, Logan R: Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom. Aliment. Pharmacol. Ther. 21, 1217-1224 (2005).
50. Landewe RB, van den Borne B, Breedveld F, Dijkmans B: Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet 355(9215), 1616-1617 (2000).
51. Infliximab: Drug Information. Lexi-Comp, Inc.. OH, USA (2006).
52. Cyclosporine: Drug Information. Lexi-Comp, Inc., OH, USA (2006).
53. Colombel JF, Loftus E, Tremaine W et al.: The saftey profile of infliximab in patients with crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 126, 19-31 (2004).
54. Mesalamine: Drug Information. Lexi-Comp, Inc., OH, USA (2006).
55. Lichtenstein GR, Abreu M, Cohen R, Tremaine W: American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130, 940-987 (2006).
56. American Gastroenterological Association Medical Position Statement: Guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 124(3), 791-794 (2003).
57. Chapman JR, Larson D, Wolff B et al.: Ileal pouch-anal anastomosis: does age at the time of surgery affect outcome? Arch. Surg. 140, 534-539 (2005).
58. Almogy G, Sachar D, Bodian C, Greenstein A: Surgery for ulcerative colitis in elderly persons: changes in indications for surgery and outcome over time. Arch, Surg. 136, 1396-1400 (2001).
59. Norris B, Solomon M, Eyers A, West R, Glenn D, Morgan B: Abdominal surgery in the older Crohn's population. Aust. NZ J. Surg. 69, 199-204 (1999).
60. US Bureau of the Census. Current Population Reports, Special Studies, Sixty-five Plus in America. Government Printing Office, Washington DC, US (1993).